Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab ASCHIX:GMABC 95 Return-on-Tangible-Asset is 6.60% as of Mar. 2026, which is 67% below its 10-year median of 20.21. GuruFocus rates CHIX:GMABC with a GF Score™ of 95/100 and a GF Value™ of kr2,309.15 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Genmab AS ranks better than 95.48% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Genmab AS's annualizedNet Income for the quarter that ended in Mar. 2026 was kr1,371 Mil. Genmab AS's average total tangible assets for the quarter that ended in Mar. 2026 was kr20,761 Mil. Therefore, Genmab AS's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 6.60%.
The historical rank and industry rank for Genmab AS's Return-on-Tangible-Asset or its related term are showing as below:
CHIX:GMABc'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 13.04 Med: 20.21 Max: 27.02
Current: 19.96
During the past 13 years, Genmab AS's highest Return-on-Tangible-Asset was 27.02%. The lowest was 13.04%. And the median was 20.21%.
CHIX:GMABc's Return-on-Tangible-Asset is ranked better than 95.48% of 1416
companies
in the Biotechnology industry
Industry Median: -35.915
vs CHIX:GMABc: 19.96
Genmab AS (CHIX:GMABc) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Genmab AS Return-on-Tangible-Asset Related Terms
Genmab AS Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Genmab AS's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:GMABC vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Genmab AS's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Genmab AS's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 6.60% mean?
Genmab AS (CHIX:GMABC) has a Return-on-Tangible-Asset of 6.60% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Genmab AS and its competitors. This is 67% below median its historical median of 20.21. Over the past decade, Genmab AS's Return-on-Tangible-Asset has ranged from 13.04 to 27.02. According to the industry distribution chart, Genmab AS ranks #64 out of 1416 companies in the Biotechnology industry, placing it in the top 4.5%.
Is Genmab AS's Return-on-Tangible-Asset too high?
Genmab AS's current Return-on-Tangible-Asset of 6.60% is 67% below median its 10-year median of 20.21. Over the past 10 years, this metric has ranged from a low of 13.04 to a high of 27.02. Based on the distribution chart, Genmab AS ranks #64 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #64 out of 1416 companies for Return-on-Tangible-Asset. This places Genmab AS in the top 5% of its industry — outperforming the majority of peers. Historically, Genmab AS's own Return-on-Tangible-Asset has ranged from 13.04 to 27.02 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Genmab AS and its competitors. Genmab AS's current Return-on-Tangible-Asset is 6.60%, which is 67% below median its own 10-year median of 20.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2,309.15, compared to a current price of kr1,847.50 — trading 20% below its estimated fair value. The current Return-on-Tangible-Asset is 6.60%, which is 67% below median its 10-year median of 20.21. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Return-on-Tangible-Asset is 6.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of kr1,847.50 is trading 20% below its estimated GF Value™ of kr2,309.15.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for CHIX:GMABC:
Return-on-Tangible-Asset: 6.60% (67% below median its 10-year median of 20.21)
GF Value™: kr2,309.15 vs. price of kr1,847.50 (20% below fair value)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score
Get the complete analysis for CHIX:GMABC
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
